Relay Therapeutics Q1 net loss $77M; cash runway into 2029, RLY-2608 Phase 3 on track

Relay Therapeutics, Inc.

2025-Q1 EPS reported -$0.46 revenue$7,679,000

Net loss $77.1M ($0.46/share) vs $81.4M ($0.62/share) in Q1 2024; revenue $7.7M from Elevar license completion.
Cash $710.3M; runway extended into 2029, funding ReDiscover-2 past topline and vascular malformations proof-of-concept.
Phase 3 ReDiscover-2 trial of RLY-2608+fulvestrant in breast cancer on track for mid-2025; ASCO abstract accepted.
Initiated Phase 1 RLY-2608 vascular malformations trial in Q1 2025.
Reduced workforce by ~70; research run rate cut ~80%; out-licensed RLY-4008 to Elevar with downstream economics.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.